Merck & Company Inc (0QAH)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 144.98 |
|---|---|
| 52-week range | 74.96 – 157.32 |
| Return, 1 month / 3 months | −1.9% / +11.3% |
| Return, 1 year / 3 years | +67.7% / +50.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 49 |
| Volatility (1 year) | 36.7% |
| Worst drawdown (1 year) | -13.9% |
| Average daily value traded | 3.96M USD |
| Dividend yield | 0.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Merck & Company is a pharmaceutical company based in the United States that discovers, develops and sells prescription medicines, vaccines and animal health products. Its human health business serves patients and physicians through treatments for cancer, infectious disease, diabetes and cardiovascular conditions, while its animal health arm supplies veterinary medicines and vaccines to livestock and companion animal owners. The company sells its products to wholesalers, hospitals, pharmacies and government health programmes around the world.
Merck & Company Inc trades under the code 0QAH on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Merck & Company Inc (0QAH) trades on the London Exchange in UK. It last closed at USD 144.98 on 23 October 2026.
Its price-based Market X-Ray is 72 out of 100 (a strong price profile), ranking 433 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 67.7% and over the last three months it rose 11.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 83 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.9% | ||
| From 52-week high | -7.3% | ||
| Momentum | 86 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 11.3% | ||
| 6-month return | 26.4% | ||
| 12-month return, skipping the last month | 71.0% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 36.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -13.9% | ||
| Liquidity | 66 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.96M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 25 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −1.0% |
|---|---|
| 1 month | −1.9% |
| 3 months | +11.3% |
| 6 months | +26.4% |
| 1 year | +67.7% |
| 3 years | +50.0% |
| 5 years | +103.5% |
Signals
| 50-day / 200-day average | 147.03 / 126.21 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 5.08 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 Dec 2025 | USD 0.8500 |
| 12 Sep 2025 | USD 0.8100 |
| 13 Jun 2025 | USD 0.8100 |
| 14 Mar 2025 | USD 0.8100 |
| 13 Dec 2024 | USD 0.8100 |
| 13 Sep 2024 | USD 0.7700 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.